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ABSTRACT
Introduction: Dietary phytochemicals are found in
plant-based foods such as fruits, vegetables and grains
and may be categorised in a nested hierarchical
manner with many hundred individual phytochemicals
identified to date. To associate phytochemical intakes
with positive health outcomes, a fundamental step is to
accurately estimate the dietary phytochemical intake
from foods reported. The purpose of this systematic
review protocol is to describe the process to be
undertaken to summarise the evidence for food-based
dietary phytochemical intakes and health outcomes for
adults.
Methods and analysis: The review will be
undertaken following the PRISMA guidelines and the
Cochrane Handbook for Systematic Reviews of
Interventions using the Review Manager software.
Phytochemical subclasses (phenolic acids, flavanols,
etc) will be used to search for relevant studies using
the Web of Science and Scopus scientific databases.
The retrieved studies will be screened based on
inclusion of natural whole food items and health
outcomes. Phytochemical studies related to
cardiovascular disease, cancer, overweight, glucose
tolerance, digestive, reproductive, macular and bone
health and mental disorders, fatigue and immunity
will be examined based on prior scoping. The
evidence will be aggregated by the food types and
health outcomes. Comparison of differences in the
outcomes for randomised controlled trials and
observational studies will be undertaken.
The strength of the review lies in its focus on
whole food items and health conditions rather than
one type of phytochemical related to one single
health condition. Subgroup and sensitivity
analyses will be conducted where an adequate
number of publications are found per phytochemical
subclass.
Dissemination: By comparing the outcomes from
experimental and observational studies, the review
will determine whether the overall conclusions
related to the phytochemical subclasses are the
same between study types for the identified health
conditions. This is useful to public health
policymakers and health professionals alike.
Trial registration number: #CRD42014015610.
BACKGROUND
Dietary phytochemicals are commonly found
in plant-based foods such as fruits, vegeta-
bles, grains and tea.1 Consumption of total
phytochemical intake is consistently linked
with protection from chronic diseases,2
including cardiovascular disease,3–5 cancer6 7
and neurodegenerative diseases.8 In order to
associate phytochemical intakes from food
with positive health outcomes, a fundamental
step is to accurately estimate dietary phyto-
chemical intakes. Despite the ﬁrst estima-
tions of phytochemical intake from food at a
population level being reported more than a
decade ago, the methods currently employed
have evident ﬂaws.9 Traditional methods of
dietary assessment require a recall or docu-
mentation of food intakes from a given time
period in either a prospective or retrospect-
ive manner.10 To determine the nutrient
composition of individual or group intakes,
this dietary intake data needs to be con-
verted to an estimated consumption of the
‘nutrient’ of interest. This can be performed
by applying a phytochemical food compos-
ition database (FCDB) to the dietary intake
data.11
Aside from the limitations associated with
each dietary assessment method,10 there are
also several well-documented problems asso-
ciated with using FCBDs to assign phyto-
chemical content (including type and
concentration) to selected foods, resulting in
large variations in estimates of intake.9 12
First, estimation of dietary phytochemical
intake is only as comprehensive as the FCDB
used. If, for example, a database does not
have an extensive list of food items and the
phytochemical content of a food in an indivi-
dual’s diet cannot be assigned or matched to
its closest equivalent,13 then an individual’s
intake will be underestimated. This is particu-
larly challenging when analysing food intake
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data from a country that does not have a phytochemical
FCDB speciﬁc to the food supply, resulting in signiﬁcant
sources of phytochemicals not being captured.14 The
primary FCDBs used by studies (USDA, Phenol Explorer
and Euro FIR-eBASIS) provide extensive information on
the individual phytochemicals in foods, with additional
details provided for the variability of phytochemical con-
tents in foods, as well as the values associated with pro-
cessing. It is interesting to note that using different
FCDB may substantially inﬂuence the estimation of
phytochemical intake in a study, as highlighted by a
recent comparison between estimates of dietary phyto-
chemical intake produced by the US Department of
Agriculture (USDA) and Phenol Explorer databases.15
However, this is not a well-researched concept and needs
further veriﬁcation. Second, the phytochemical content
of speciﬁc foods is highly variable and inﬂuenced by a
foods growth, harvest and processing conditions.
Disregarding the processes by which foods are produced
and the impact on the phytochemical levels may lead to
an overestimation of the phytochemical intakes. A phyto-
chemical FCBD is unable to account for all of the vari-
ability and can only provide an estimate for each food
consumed. Finally, estimating dietary phytochemical
intakes through dietary assessment is unable to account
for the high intraindividual variation associated with
phytochemical metabolism and absorption, which is
inﬂuenced by factors other than intake, such as bioavail-
ability and genetic factors.
Rationale
Description of the problem or issue
Dietary phytochemicals are bioactive compounds that
are commonly found in plant-based foods such as fruits,
vegetables, grains and tea. Many studies, including
animal models, population observations and clinical
trials, have been conducted to investigate the protective
effects of dietary phytochemical intakes from food.16–21
Phytochemicals may be categorised in a nested hier-
archical manner of classes and subclasses. For example,
total polyphenols comprises ﬂavonoids, phenolic acids,
lignans and other polyphenol groups.22 Flavonoids can
be further divided into anthocyanins, ﬂavan-3-ols, ﬂava-
nones, ﬂavones, ﬂavonols, isoﬂavones and proanthocya-
nidins subclasses.22 Current published reviews tend to
focus only on the relationship between a single subclass
of phytochemical and one health condition regardless
of the source of phytochemical, that is, compound
extraction and synthesis, or from whole food source.23–28
Although it is valuable to isolate the speciﬁc phytochem-
ical to reveal their mechanism of action, it may be prob-
lematic in reﬂecting dietary consumption. People eat
food and therefore dietary phytochemical research
should consider the whole food matrix.
Many whole foods, such as apples, blueberries, broc-
coli, cherries, soy beans and walnuts, are naturally rich
in phytochemicals, but are also high in micronutrients
and ﬁbres.29 30 As phytochemical compounds do not
exist in isolation in these foods, the whole food matrix
may play a role in the protective effects of phytochem-
icals. It has been suggested that phytochemicals con-
sumed as a part of their natural food matrix may be
more bioactive than a high dose of isolated phytochem-
icals provided by dietary supplements.31 This may be
attributed to phytochemicals working synergistically with
other phytochemicals that are inherently present in the
food.32 Furthermore, their bioactivity may also be attrib-
utable to the interactions between the phytochemicals
and other nutrients (eg, vitamin C)31 or other constitu-
ents or contaminants in the food. For example, polyphe-
nols found in whole grain foods have been considered
to contribute to the health beneﬁts observed.33
However, the health beneﬁts of whole grain consump-
tion related to polyphenols may also be linked to the
cereal ﬁbre or other components that naturally occurs
in the grain.34 Such patterns cannot be determined by
isolating the phytochemicals. Reviews have been con-
ducted previously for speciﬁc phytochemical-rich whole
food items such as strawberries;35 however, the focus
remained on single phytochemical subclasses, namely,
strawberry polyphenols. Such reviews should consider
the synergistic interactions occurring within the
phytochemical-rich whole food matrix. Although other
nutrients, such as micronutrients and ﬁbre, naturally
occur in phytochemical-rich whole foods, the phyto-
chemical content of a given whole food can be esti-
mated using dietary assessment tool and phytochemical
FCDBs, which can be further compared across the
studies. Thus, grouping and analysing phytochemical
content of phytochemical-rich whole foods can still be
achieved, but may also need to take into account the
foods synergistic effect and human consumption habits.
Examining phytochemical-rich whole foods rather than
speciﬁc classes of phytochemicals may reﬂect the dietary
consumption characteristics that are in turn translatable
to dietary advice.
Translation to dietary advice also requires consider-
ation of the health conditions being addressed. Common
risk factors and biomarkers have been found for different
diseases, particularly lifestyle-related chronic diseases
such as cardiovascular disease, type 2 diabetes mellitus
and various forms of cancer. Endothelial dysfunction bio-
markers including E-selectin, intercellular adhesion mol-
ecule 1 and vascular cell adhesion molecule 1 are
common risk factors related to cardiovascular diseases
and type 2 diabetes mellitus,36 37 while inﬂammatory bio-
markers such as C-reactive protein are common to the
development of type 2 diabetes mellitus and cancer.38 39
Therefore, this review will consider a range of whole food
items and disease states, which to date have not been
addressed in reviews of this nature.
Another limitation hindering the interpretation of
phytochemical studies are the differences between
observational and experimental research outcomes that
demonstrate associations of dietary phytochemical
intakes with speciﬁc health outcomes.5 40 Population-
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based observational studies often provide evidence of
associations between diet and disease, while experimen-
tal studies, particularly randomised controlled trials, are
designed to reduce bias and confounding to reveal rela-
tionships via hypothesis testing of outcomes from these
observational studies.41 A comparison of outcomes
related to phytochemical intakes in observational and
experimental research is imperative to interpret current
ﬁndings across the literature and to provide recommen-
dations for future research.
Description of the methods being investigated
Figure 1 provides an overview of the proposed approach
to the systematic literature review to be conducted. There
are currently numerous methods used to measure dietary
phytochemical intakes in different settings. This system-
atic review will consider studies that use any form of
dietary assessment translated to ‘nutrient’ data to estimate
consumption of dietary phytochemicals or the intake of
speciﬁc phytochemical-rich food items. Although it is
recognised that biomarkers of intake may be used as a
means to measure intake, studies using biomarkers of
intake will not be included in the review. Validation and
methodological studies for dietary assessment tools will
also be excluded as the outcomes are unlikely to relate to
the health outcomes, the focus of the review.
How these methods might work
The proposed review will consider the various subclasses
of the phytochemical class overall. Although the evi-
dence aggregation will be based on individual food
items, it will speciﬁcally focus on the whole food matrix
and its nutrient synergies. For example, foods high in
whole grains are also high in dietary ﬁbre and polyphe-
nols, a class of phytochemical. For this review, the inte-
rest is related to the polyphenols content of the
wholegrain foods rather than the dietary ﬁbre.
Therefore, the speciﬁc phytochemical compounds will
be used to search for the relevant studies to capture the
various subclasses of the phytochemical class overall. As
common risk factors and health biomarkers are shared
across different health conditions, as demonstrated
above, the health outcomes will not be limited during
the key word searches. The health outcomes-related
phytochemical studies will be identiﬁed during the study
abstract screening phase. In the evidence synthesis
phase, the phytochemical content of phytochemical-rich
whole foods will be extracted and summarised based on
the reported values and units. The identiﬁed values will
be used as a benchmark to compare across studies.
Finally, aggregation of evidence based on the individual
foods rather than the phytochemical classes is more
likely to reﬂect eating behaviours, as different phyto-
chemical compounds may have positive protective
effects on the same biomarker or health outcome. For
example, brassica vegetables such as broccoli, Brussels
sprouts and cabbage are naturally low in ﬂavonoid com-
pounds though are high in glucosinolates.42 Flavonoids
and glucosinolates are phytochemicals and have demon-
strated protective effects related to cancer risk in human
population studies.43 44 Thus, the proposed approach to
the systematic literature review will provide novel insight
into health outcomes associated with phytochemical-rich
food consumption, while considering eating behaviours.
Within the studies, the methods used to determine the
phytochemical content of the food items will be consid-
ered to determine if there is consistency within the
health outcome categories of interest.
Why it is important to do this review
As stated earlier, current reviews with phytochemicals
focus on one health condition and/or one speciﬁc sub-
class of phytochemical, for example, anthocyanins.
Further to this, other reviews focus on either experimen-
tal or observational study designs, but do not attempt to
compare both.45–47 Although the workload substantially
increases when considering all studies, this will allow the
current review to determine whether the conclusions
being made by the differing study types are consistent.
In addition, focussing on phytochemicals from whole
food sources rather than from a process of compound
extraction and/or synthesis again relates to eating beha-
viours. By considering a range of phytochemical sub-
classes and health outcomes, this review will relate
outcomes to the whole food matrix of different foods
rather than focusing on a single speciﬁc food compo-
nents which to date have also not been addressed.
Objectives
The purpose of this review is to summarise and synthe-
sise the evidence about dietary phytochemical intakes
from whole foods related to health outcomes in rando-
mised and non-randomised food-based trials, prospective
and retrospective cohort, case–control, cross-sectional
studies that aim to measure or estimate dietary phyto-
chemical intakes in adults. The speciﬁc question that
the review following this protocol will address utilises a
PICO format and is proposed as: In food-based studies
for phytochemical intake, what is the impact on chronic
disease outcomes for adults?
Figure 1 Overview of the proposed approach to the
systematic literature review to be conducted.
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The following questions will also be used guide the lit-
erature search:
▸ What is the primary health outcome reported from
the study and how does this relate to chronic disease?
▸ Does the study focus on whole foods, not supplements?
▸ Are the phytochemical outcomes a primary focus to
the ‘nutrients’ reported for the study?
It is hypothesised that the review will show an association
between the number of studies related to a phytochemical
subclass and consistency of the outcomes reported.
METHODS
This review was registered with the International
Prospective Register of Systematic Reviews (PROSPERO)
under the registration number #CRD42014015610.
The structure of this review protocol follows the
Preferred Reporting Items for Systematic Review and
Meta-Analyses (PRISMA) guidelines and the recommen-
dations of the Cochrane Handbook for Systematic
Reviews of Interventions using Review Manager
(RevMan) Computer program, V.5.3.5, Copenhagen:
The Nordic Cochrane Centre, The Cochrane
Collaboration, 2014. This protocol was developed in line
with the PRISMA-P 2015 checklist.48 49
Eligibility criteria for considering studies
Types of studies
This review will include randomised, non-randomised
food-based trials and crossover food-based trials, and
analytical epidemiological study designs including pro-
spective and retrospective cohort, case–control and
cross-sectional studies.
Types of participants
No restrictions will be set for the age or gender of parti-
cipants, though participants must be diagnosed with a
chronic disease. These chronic diseases will be used for
subgroup statistical analyses.
Setting and time frame
Studies will be restricted to those published from
January 2004 to March 2016 to ensure the literature is
relevant. Studies published before 2004 are not included
due to a focus on mechanistic studies as identiﬁed
during the scoping phase.
Types of data
The main data will be the dietary phytochemical intakes
from foods related to health outcomes from different study
designs. The details of study characteristics and consump-
tion of phytochemicals will be examined. The trends and
patterns of dietary phytochemical intake from foods and
health outcomes in different study designs will be explored.
Types of methods
Studies reporting data for whole food-based phytochem-
ical outcomes in relation to a health condition will be
included. Studies that do not measure whole foods or
whole of diet-based phytochemical intakes (ie, encapsu-
lated phytochemicals extract, extract from herbal sources
and puriﬁed or modiﬁed version of phytochemicals) and
other mechanistic studies (ie, bioavailability or mechanis-
tic feeding studies) will be excluded. The phytochemical-
containing foods must be identiﬁed as naturally contain-
ing phytochemicals (with a reference to a study character-
ising the phytochemical composition of the food, or
reference to a comprehensive FCDB). The identiﬁed
phytochemical-rich food must also be commercially avail-
able or publicly accessible by a general population.
Information sources
The search aims to ﬁnd published and unpublished
studies through electronic scientiﬁc databases, the Internet
and reference lists of included studies. Key terms have
been developed (see online supplementary appendix 1).
The initial phase will consist of searches of the following
databases as the two largest health-related databases:
▸ Web of Science
▸ Scopus
Only studies published in the English language will be
considered for inclusion due to a lack of translation
resources. Ongoing clinical trials will be searched for
using the Australian Government National Health and
Medical Research Council and Department of Industry,
Innovation and Science Clinical trials registries (https://
www.australianclinicaltrials.gov.au/clinical-trial-registries)
using the phytochemical subclasses listed in online
supplementary appendix 1.
Search strategy
An example search strategy as applied to the Scopus scien-
tiﬁc database is shown below including limits to the year
of publication, document type and a focus on human
studies to exclude many of the mechanistic studies.
(TITLE-ABS-KEY (lignans OR ‘ﬂavan-3-ol*’ OR terpene*
OR carotenoid* OR limonoid* OR phytosterol* OR thiol*
OR glucosinolate* OR indole* OR isoprenoid* OR ‘Lipoic
acid’ OR ubiquinone OR ‘Phenolic acid’ OR ﬂavonoid* OR
ﬂavanol* OR tannin* OR stilbene* OR lignans OR isoﬂa-
vone* OR anthocyanin* OR ﬂavanone* OR ﬂavonol* OR
ﬂavone* OR allicin OR capsaicin OR catechin OR ‘Ellagic
acid’ OR genistein OR lycopene OR saponin* OR zeax-
anthin OR polyphenol*) AND TITLE-ABS-KEY
(((randomi?ed W/6 control) AND (trial OR study)) OR
(cohort W/6 stud*) OR (longitudinal W/6 stud*) OR
‘panel stud*’) AND NOT TITLE-ABS-KEY (rat OR mice OR
cell)) AND PUBYEAR > 2004 AND (LIMIT-TO (DOCTYPE,
‘ar’) OR LIMIT-TO (DOCTYPE, ‘re’) OR LIMIT-TO
(DOCTYPE, ‘ip’)) AND (LIMIT-TO (EXACTKEYWORD,
‘Human’) OR LIMIT-TO (EXACTKEYWORD, ‘Humans’))
Study records
Selection process
The review will be structured and reported according to
PRISMA. One review author (YCP) will conduct the litera-
ture search in the speciﬁed scientiﬁc databases. Results of
4 Probst YC, et al. BMJ Open 2017;7:e013337. doi:10.1136/bmjopen-2016-013337
Open Access
the search will be collated in the reference management
software Endnote (version X7.5, Thomson Reuters, 2016).
Duplicate publications will be excluded. Two review authors
(KK and VXG) will independently screen publications
using the criteria (table 1) for inclusion. Resolution of any
disagreements will occur through discussion and required
consultation with a third reviewer (YCP) for consensus.
The observational studies will be considered separately
to other studies to determine any differences in
methods reported. Articles identiﬁed by database
searches will be assessed for relevance to the review
based on the title and abstract (table 1). For those
meeting the inclusion criteria, the full-text publications
will be retrieved and assessed for relevance to the review
criteria. A PRISMA ﬂow diagram of the search strategy
and selection process will be developed.
Data extraction and data management
Eligibility for inclusion will be conﬁrmed by an independ-
ent researcher (SM). Data extracted from the studies will
be entered into RevMan software V.5.3.5 by the same
researcher. Data accuracy will be checked by double data
entry having one review author (VXG) entering data into
a separate ﬁle and comparing the results for a subset of
studies. Consensus will be sought by consultation with a
third researcher (YCP). When the information regarding
any of the above is unclear, YCP will attempt to contact
authors of the original publication to provide further
details. The studies will be grouped, described and evalu-
ated in accordance with their methodological similarities.
Studies will also be separated into their experimental or
observational design. Studies will be further grouped by
their health condition and phytochemical subclass.
Data items
Data collection process
To ensure internal bias is minimised, the review will be
undertaken by more than one researcher with quality
assessed between the methods of data extraction.
Outcome measures and prioritisation
Primary outcomes
The primary outcome is the summary of dietary phyto-
chemical intakes from foods by subclass and health out-
comes from different study designs. The phytochemical
subclasses were determined based on the classiﬁcation
system outlined in the Handbook of plant food
phytochemicals.22
This review will consider studies that investigate dietary
phytochemical intake from whole foods by addressing at
least one of the following health outcomes:
Health outcomes:
▸ Cardiovascular disease
– Cholesterol
– Heart disease
– Hypertension
– Blood pressure
▸ Cancer
– Oxidative stress
– DNA damage
▸ Overweight
– Obesity
– Weight loss
▸ Body composition
▸ Glucose tolerance
– Diabetes mellitus (type 1 and 2)
– Metabolic syndrome
▸ Digestion
– Gastrointestinal tract
– Constipation
Table 1 Overall inclusion and exclusion criteria for publication screening
Section Criteria
Include
if:
Language Publication reported in English Yes
Design Randomised or non-randomised food-based trials, or prospective or retrospective cohort or, case–
control, cross-sectional studies
Yes
Case reports, reviews, editorials, letter to the editor, qualitative research No
Population Adults aged 18+ years Yes
Animal studies or studies including <18 years No
Content ▸ Studies examining the relationship between total or specific dietary phytochemical intake from
foods and health outcomes
▸ The intervention advises participants to consume foods rich in phytochemicals:
– Natural whole food, include powder and puree which are food composition complete, such as
blueberries and apple
– Natural whole food juice or drink, such as apple juice
– Complex food, which contains more than one whole food ingredients combination, for example,
fortified bread or cereal bar
▸ Studies examining encapsulated phytochemicals, extract from herbal sources and purified or
modified version of phytochemicals.
▸ Mechanistic studies (ie, bioavailability or mechanistic feeding studies)
Yes
Yes
No
No
Access Full-text article accessible Yes
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▸ Reproductive health
▸ Macular health
▸ Bone health
▸ Mental health
– Cognitive processes
– Cognition
– Mood
– Attention
– Memory
▸ Fatigue
▸ Immunity
The health outcomes are based on preliminary
scoping searches in relation to the topic area being pro-
posed (table 2). Owing to the variability of the health
conditions, the speciﬁc outcomes of interest will be tar-
geted based on consistency of reporting within the
studies for a health condition and in turn for a phyto-
chemical subclass. The authors will consider the require-
ment for a three-part review series capturing
cardiovascular disease, cancer and other health condi-
tions where consistency is apparent. This will be deter-
mined following application of the inclusion criteria to
the publications retrieved from the database search. It is
likely that common factors such as height, weight, body
mass index, gender and mortality (as appropriate) can
be applied across all conditions and the principles of
the protocol applicable to a series or single review.
Assessment of reporting biases in individual studies
Systematic error as a result of bias will be considered to
account for selection bias as well as any reporting bias
that may arise within the review.
Two review authors (KK and VXG) will independently
assess the quality for each study using the Cochrane Risk
of Bias Tool50 to address the various forms of bias
related to the extracted studies. This tool will be used to
critically appraise the quality of included studies,
looking at issues of validity of included studies such as
relevance to improve current practice, randomisation,
allocation concealment, blinding, intervention descrip-
tion, validity and reliability of measurements, missing
data, selective reporting. Studies will be scored as low,
unclear or high according to the speciﬁed criteria.
Studies will not be excluded on the grounds of their
quality, but the review will report methodological quality
when presenting the results.
Data synthesis
All results will be subject to a rigorous quality assessment
process to ensure data quality is upheld. For all aims,
ﬁndings will be presented as a narrative synthesis, as well
as tables and ﬁgures. Data synthesis and required statis-
tical analyses as outlined below will be conducted by
YCP and VXG.
Dealing with missing data
Where key data are missing from the included publica-
tions, the review authors will attempt to contact
corresponding authors (or other authors if necessary) of
included studies. If this information is not achievable,
the data will not be imputed and a note will be made
that the study did not provide data for the particular
outcome.
Sensitivity analysis
Although it is unlikely that a meta-analysis will be con-
ducted with the data extracted, sensitivity will be consid-
ered to ensure the decision-making process was robust.
It will demonstrate the inﬂuence of the abovementioned
potentially missing data with and without imputations
on the ﬁndings of the review. Further to this during the
review process, abstracts that do not contain sufﬁcient
data will be included rather than excluded and progress
to a second review phase of full-text publications.
Studies will only be included if all participants of the
study meet the inclusion criteria. Time points at which
tools in a study are used, for example, dietary assessment
methods will also be extracted for comparability of data
trends.
Subgroup analysis and investigation of heterogeneity
Included publications will be grouped by their phyto-
chemical subclass to determine patterns of reporting in
relation to assessment tools used. The weighted mean
difference of the intervention and control groups for
randomised controlled trial studies will be calculated
and presented with 95% CIs. If mean values are not pro-
vided in the publication, it will be computed using CIs
and the SEM. Heterogeneity of the participant popula-
tion data will be conﬁrmed using a random effects
model. Any abnormal data points will be checked to
ensure incorrect data have not been reported. χ2 and
I2 tests will be conducted to determine the level of het-
erogeneity. The 95% CI of the I2 will be presented and
75% will be identiﬁed as considerable heterogeneity.50
High variability of the data is expected.
Meta-bias(es)
Bias related to the systematic error, selective reporting or
publication bias will be considered for all studies
included in the review. This will be determined using
Funnel plots. The scale reversed SE plotted against the
effect estimate with 95% CIs will be considered to address
small sample size bias. This will be indicative of an asym-
metrical plot where the log of the OR to be considered.
Confidence in cumulative evidence
The strength of the body of evidence will be assessed for
each health outcome addressed in the review using the
Grading of Recommendations Assessment, Development
and Evaluation (GRADE) instrument.50 This includes
consideration of the study limitations, indirectness,
inconsistency, imprecision, publication bias within the
studies related to the health outcomes.
6 Probst YC, et al. BMJ Open 2017;7:e013337. doi:10.1136/bmjopen-2016-013337
Open Access
Table 2 Preliminary scoping of publications grouped by phytochemical subclass
Review
Subclass21
Total
publications* Biomarker CVD
Cancer
protection
Cancer
care
Mental
health
Other
disease Food-related Non-food-related
Purified
component
Total health
outcomes
Phenolic acids 138 20 15 15 1 2 8 16 42 9 46
Flavonoids 678 21 104 24 41 14 45 84 283 22 260
Flavanols 26 0 13 1 1 3 1 3 4 0 19
Tannins 172 0 4 0 0 0 5 0 163 0 9
Stilbenes 63 3 0 0 0 0 3 7 49 0 3
Lignanss 133 14 13 1 22 3 23 10 28 6 67
Isoflavones 706 44 28 12 56 3 75 71 209 9 362
Anthocyanins 49 1 4 3 0 0 6 4 25 4 13
Flavanones 11 2 0 0 0 0 0 0 9 0 0
Flavonols 28 0 1 3 1 1 1 7 15 0 7
Flavones 14 0 0 0 0 0 0 1 13 0 0
Allicins 16 0 0 0 0 0 0 5 6 0 5
Capsaicins 609 0 1 1 0 0 13 3 590 1 15
Catechins 143 2 5 3 3 0 11 14 105 0 22
Ellagic acids 12 0 0 0 0 0 0 0 12 0 0
Genisteins 0 0 0 0 0 0 0 0 0 0 0
Lycopenes 116 4 8 8 17 0 10 7 56 0 43
Saponins 72 1 0 0 0 0 0 0 70 1 0
Zeaxanthins 73 3 0 1 1 0 13 5 50 0 15
Polyphenols 244 8 40 13 17 3 26 30 98 8 99
Flavan-3-ols 66 2 13 4 12 9 6 6 6 4 44
Total 3369 125 249 89 172 38 246 273 1833 64 1029
*Where summation of the row exceeds the total number, this is due to inclusion of multiple component in one publication, for example, biomarker and disease outcomes.
CVD, cardiovascular disease.
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Management and review dissemination
The processes of review and synthesis outlined in this
protocol will be undertaken by at least two members of
the review team to ensure quality assurance throughout
the review. Management of the review team will be
upheld by YCP. The entire review team will meet follow-
ing completion of each stage of the review. By compar-
ing the outcomes from experimental and observational
studies, this review will determine whether the overall
conclusions related to the phytochemical subgroups are
the same for the identiﬁed health conditions useful to
public health policymakers and health professionals
alike. Review papers to date are often focused on only
one phytochemical class or for meta-analyses only focus
on randomised controlled trials. By considering all of
the evidence for the growing research into phytochem-
icals, the proposed review will provide readers with a
comprehensive update of food-related studies and their
impact on health.
Twitter Follow Yasmine Probst @YasmineProbst
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